Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Income towards Parent Company came in at -$24.8 million in Q1 2026, down 27.72% year-on-year from -$34.2 million in Q1 2025, and down 487.22% on a QoQ basis from $6.4 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 6 years of Income towards Parent Company data on file, last reported at -$24.8 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 27.72% year-over-year to -$24.8 million in Q1 2026; TTM through Mar 2026 was -$60.5 million, a 22.77% increase from a year earlier, with the FY2025 full-year figure at -$160.1 million, down 1.18% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$24.8 million, down from $6.4 million in the prior quarter.
- Over the last five years, Income towards Parent Company for OBIO reached as high as $6.4 million in Q4 2025 and fell as low as -$25.2 million in Q2 2024.
- Historically, Income towards Parent Company has averaged -$14.8 million across 5 years, with a median of -$16.1 million in 2024.
- Across the five-year window, Income towards Parent Company slumped 8300.5% in 2022 and jumped 139.71% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$10.2 million in 2022, then decreased by 20.09% to -$12.2 million in 2023, then sank by 31.95% to -$16.1 million in 2024, then jumped by 139.71% to $6.4 million in 2025, then tumbled by 487.22% to -$24.8 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$24.8 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.76 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | -20.54 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -19.38 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Sep 30, 2024 | -17.62 Mn |
| Jun 30, 2024 | -25.19 Mn |
| Mar 31, 2024 | -15.80 Mn |
| Dec 31, 2023 | -12.20 Mn |
| Sep 30, 2023 | -22.02 Mn |
| Jun 30, 2023 | -16.96 Mn |
| Mar 31, 2023 | -11.90 Mn |
| Dec 31, 2022 | -10.16 Mn |
| Sep 30, 2022 | -10.45 Mn |
| Jun 30, 2022 | -7.89 Mn |
| Mar 31, 2022 | -5.36 Mn |
| Dec 31, 2021 | -122,045.00 |
| Sep 30, 2021 | -124,445.00 |
| Jun 30, 2021 | -126,318.00 |